Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancerv

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Zardan, A ^a   Nip, K M ^a   Thaper, D ^a   Toren, P ^a   Vahid, S ^a   Beraldi, E ^a   Fazli, L ^a   Lamoureux, F ^a   Gust, K M ^a   Cox, M E ^a   Bishop, J L ^a   Zoubeidi, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN 90; PROTEASOME; PROTEIN KINASE LYN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISSOCIATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION; UPREGULATION; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CORRELATION ANALYSIS; GENE EXPRESSION REGULATION; IN VIVO STUDY; PROSTATE CANCER; PROTEIN STABILITY; TRANSCRIPTION INITIATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84907352744     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.30     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187-1197.
3. Ryan CJ. Abiraterone: current and future use in prostate cancer. Clin Adv Hematol Oncol 2012; 10: 180-181.
4. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-506.
5. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1998; 1: 289-296.
6. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792-4798.
7. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci USA 2012; 109: 1643-1648.
8. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006; 10: 309-319.
9. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104: 8438-8443.
10. Benati D, Baldari CT. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr Med Chem 2008; 15: 1154-1165.
11. Engen JR, Wales TE, Hochrein JM, Meyn MA 3rd, Banu Ozkan S, Bahar I et al. Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 2008; 65: 3058-3073.
12. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
13. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 3540-3549.
14. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004; 64: 1058-1066.
15. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54: 2577-2581.
16. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-3333.
17. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
18. Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA, Witte ON. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci USA 2011; 108: 6579-6584.
19. Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, Grellscheid SN et al. Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS ONE 2011; 6: e29088.
20. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67: 10455-10465.
21. Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002; 7: 55-64.
22. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 2005; 95: 1320-1326.
23. Pratt WB, Morishima Y, Osawa Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 2008; 283: 22885-22889.
24. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-1697.
25. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT. A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 2005; 312: 546-553.
26. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 2005; 35: 547-555.
27. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546-5552.
28. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits sitespecific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 2010; 29: 3208-3216.
29. Trentin L, Frasson M, Donella-Deana A, Frezzato F, Pagano MA, Tibaldi E et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008; 112: 4665-4674.
30. Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell 2009; 33: 43-52.
31. Verhagen AM, Wallace ME, Goradia A, Jones SA, Croom HA, Metcalf D et al. A kinase-dead allele of Lyn attenuates autoimmune disease normally associated with Lyn deficiency. J Immunol 2009; 182: 2020-2029.
32. Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manage Res 2013; 6: 25-30.
33. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
34. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT et al. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnol 2008; 26: 127-132.
35. Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306-314.
36. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinibresistant leukemia. Blood 2005; 106: 3948-3954.
37. Kasahara K, Nakayama Y, Ikeda K, Fukushima Y, Matsuda D, Horimoto S et al. Trafficking of Lyn through the Golgi caveolin involves the charged residues on alphaE and alphaI helices in the kinase domain. J Cell Biol 2004; 165: 641-652.
38. Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013; 73: 3109-3119.
39. Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010; 70: 2307-2317.
40. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate resistant prostate cancer. Cancer Res 2011; 71: 5838-5849.